nivolumab and hyaluronidase (Opdivo Qvantig): FDA status

Approved Approved Feb 17, 2025. Indication: subcutaneous PD-1 immunotherapy for cancers including urothelial carcinoma.

Regulatory history

All products in the FDA Tracker

Loading today's edition…